This supplement was initiated and fully funded by Novo Nordisk.
Adverse event reporting information and prescribing information for Victoza® (liraglutide) can be found within the supplement.
The content has been reviewed and approved by the sponsoring company and the authors prior to publication. Editorial support for this supplement was provided by SB Communications Group.
Job code: UK/VT/0615/0336. Date of preparation: July 2015
Sign up to all DiabetesontheNet journals
By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.
Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.
We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.
Jane Diggle discusses ambiguities in licences and whether there is a role for incretin therapies for weight management in people with type 1 diabetes.
13 Sep 2026